Lana Medical Company (TADAWUL:9587)
Saudi Arabia · Delayed Price · Currency is SAR 2.370
-0.130 (-5.20%)
Sep 3, 2026, 1:14 PM AST
Lana Medical Company Income Statement
Financials in millions SAR. Fiscal year is January - December.
Millions SAR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 107.78 | 92.3 | 84.09 | 48.63 | 40.8 | 31.97 | |
Revenue Growth | 9.82% | 9.77% | 72.89% | 19.20% | 27.64% | - |
Cost of Revenue | 85.59 | 71.47 | 59.19 | 29.42 | 21.93 | 15.1 |
Gross Profit | 22.2 | 20.84 | 24.9 | 19.21 | 18.87 | 16.87 |
Selling, General & Admin | 19.51 | 18.81 | 15.3 | 11.61 | 9.04 | 8.47 |
Operating Expenses | 15.5 | 14.89 | 16.42 | 19.58 | 12.35 | 9.55 |
Operating Income | 6.7 | 5.95 | 8.48 | -0.37 | 6.52 | 7.32 |
Interest Expense | -3.13 | -2.39 | -0.48 | -0.34 | -0.2 | -0.08 |
Earnings From Equity Investments | -0.37 | -0.75 | 5.37 | - | - | - |
Other Non Operating Income (Expenses) | -0.06 | 0.21 | 0.25 | 0.18 | 0.29 | 0.54 |
EBT Excluding Unusual Items | 3.14 | 3.02 | 13.62 | -0.52 | 6.62 | 7.78 |
Gain (Loss) on Sale of Assets | 0.73 | 0.73 | - | - | - | 0.01 |
Pretax Income | 3.87 | 3.75 | 13.62 | -0.52 | 6.62 | 7.79 |
Income Tax Expense | 1.07 | 1.05 | 1.16 | 1.41 | 1.13 | 1.2 |
Net Income | 2.8 | 2.7 | 12.46 | -1.93 | 5.49 | 6.59 |
Net Income to Common | 2.8 | 2.7 | 12.46 | -1.93 | 5.49 | 6.59 |
Net Income Growth | -75.04% | -78.36% | - | - | -16.70% | - |
Shares Outstanding (Basic) | 55 | 54 | 54 | 46 | 45 | 33 |
Shares Outstanding (Diluted) | 55 | 54 | 54 | 46 | 45 | 33 |
Shares Change | 6.90% | - | 18.38% | 1.37% | 37.11% | - |
EPS (Basic) | 0.05 | 0.05 | 0.23 | -0.04 | 0.12 | 0.20 |
EPS (Diluted) | 0.05 | 0.05 | 0.23 | -0.04 | 0.12 | 0.20 |
EPS Growth | -76.65% | -78.36% | - | - | -39.25% | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -7.07 | -10.37 | -3.73 | -2.43 | 0.5 | -12.17 |
Free Cash Flow Per Share | -0.13 | -0.19 | -0.07 | -0.05 | 0.01 | -0.37 |
Dividend Per Share | 0.030 | 0.030 | - | - | - | - |
Dividend Growth | - | - | - | - | - | - |
Gross Margin | 20.59% | 22.57% | 29.61% | 39.50% | 46.25% | 52.76% |
Operating Margin | 6.22% | 6.45% | 10.08% | -0.76% | 15.99% | 22.90% |
Profit Margin | 2.60% | 2.92% | 14.82% | -3.96% | 13.46% | 20.63% |
Free Cash Flow Margin | -6.55% | -11.23% | -4.43% | -5.00% | 1.22% | -38.06% |
EBITDA | 11.62 | 10.27 | 11.18 | 1.11 | 7.54 | 8.09 |
EBITDA Margin | 10.78% | 11.13% | 13.29% | 2.29% | 18.47% | 25.30% |
D&A For EBITDA | 4.92 | 4.32 | 2.7 | 1.48 | 1.01 | 0.77 |
EBIT | 6.7 | 5.95 | 8.48 | -0.37 | 6.52 | 7.32 |
EBIT Margin | 6.22% | 6.45% | 10.08% | -0.76% | 15.99% | 22.90% |
Effective Tax Rate | 27.57% | 28.11% | 8.51% | - | 17.03% | 15.36% |
Advertising Expenses | - | 0.41 | 0.35 | 0.33 | 0.19 | - |